News and Press Releases
DARZALEX (daratumumab) Subcutaneous Formulation-based Quadruplet Therapy Regimen Shows Significant Improvement in Outcomes for Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma
Daratumumab subcutaneous-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimenFirst presentation of data from Phase 3 PERSEUS study...
Category: Clinical Trials
Posted: December 13, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
New Data Presented at ASH from the Phase 3 GLOW Study Show Fixed-Duration, First-Line Treatment with IMBRUVICA (ibrutinib) Plus Venetoclax Demonstrated an Overall Survival Rate of More Than 84% at 54 Months in Patients with Chronic Lymphocytic Leukaemia
Additional data from the phase 2 CAPTIVATE study, show 82% of patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with fixed-duration ibrutinib plus venetoclax did not need next-line treatment...
Category: Clinical Trials
Posted: December 11, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
PlaqueTec recruits first ten patients in BIOPATTERN trial
Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...
Category: Clinical Trials
Posted: November 29, 2023
Exonate announces successful completion of phase 1b/2a trial in diabetic macular oedema
Lead ophthalmology candidate EXN407 has potential to be the first topical treatment for diabetic retinopathy/diabetic macular oedema EXN407 met all endpoints and displayed encouraging biological activity in diabetic patients with...
Category: Clinical Trials
Posted: November 28, 2023
Janssen Submits Application to the European Medicines Agency forRYBREVANT▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy
The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of...
Category: Clinical Trials
Posted: November 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Commercial study set up times reduced by a third, according to new data
26 October 2023 -- London, England -- New data from the National Institute for Health and Care Research (NIHR) shows that the National Contract Value Review has significantly reduced the...
Category: Clinical Trials
Posted: October 26, 2023
Results from Phase 2 THOR-2 Study Showed Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with Erdafitinib Versus Chemotherapy
Data from Cohort 1 of the phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy 21 October 2023 --...
Category: Clinical Trials
Posted: October 23, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023
Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...
Category: Clinical Trials
Posted: October 12, 2023
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK
New Safety Data Suggests SPRAVATO▼ (Esketamine Nasal Spray) is More Tolerable and Effective Compared to Quetiapine Extended-Release (XR) in Adults with Treatment-resistant Major Depressive Disorder
• The new safety data is from the ESCAPE-TRD Phase 3b study• Additional findings from this study showed esketamine NS demonstrated a significant increase in the proportion of patients achieving...
Category: Clinical Trials, Drug Discovery
Posted: October 9, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...
Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023
Signant Health Launches Signant Biotech to Accelerate and Streamline Clinical Development for Emerging Biopharmaceutical Organisations
3 October 2023 -- Philadelphia, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the launch of Signant Biotech – an integrated clinical research...
Category: Clinical Trials
Posted: October 4, 2023
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...
Category: Clinical Trials
Posted: September 20, 2023
Mural Health Raises $8m Led by Bessemer Venture Partners to Accelerate Growth
Funding enables Mural Health to expand its Mural Link platform to modernise the clinical trial participant experience 19 September 2023 -- Pennsylvania, US -- Mural Health Technologies, a next-generation clinical...
Category: Clinical Trials
Posted: September 20, 2023
Invitation to learn from the best: Evening of insights and networking will honour a clinical data management stalwart
Prof Deborah Ashby to give the 2023 Sally Hollis Memorial Lecture in Macclesfield 13 September 2023 -- London, UK and North Carolina, US -- A leading global expert on clinical...
Category: Clinical Trials
Posted: September 18, 2023
Janssen Submits MA Application to the European MedicinesAgency Seeking Approval of Erdafitinib for the Treatment of Patients with LocallyAdvanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factorreceptor (FGFR) tyrosine kinase inhibitor, will become the first therapy targeting FGFRalterations in patients with metastatic urothelial carcinoma, one of Europe’s...
Category: Clinical Trials, Drug Discovery
Posted: September 8, 2023
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
